FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

Educators and caregiversHealthcare ProfessionalMedication Safety

Feb 3

Written By Denise Kolakowski

Consider risks and benefits of continued use versus other treatments

Learn more from the FDA

Denise Kolakowski

Do Not Use E25Bio COVID-19 Tests: FDA Safety Communication

Philips Respironics Recalls Certain Trilogy EVO Ventilators for Potential Health Risks from PE-PUR Foam